An interventional study of Subacromial Triamcinolone Acetonide and Bupivacaine and Naproxen Sodium in Long Head of the Biceps Tendinopathy, sponsored by Fatih Turkmensoy. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Fatih Turkmensoy · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Tendinopathy with a site in Turkey — 6 open to participants now, 7 under way, none of them phase 3. Tendinopathy · Turkey.
Among the 24 studies in Tendinopathy with a site in Turkey, this one has the largest enrollment of the 19 interventional ones that give a count, is the only one that started in 2021, is one of 19 with no phase, and was the 24th registered.
399 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.
Browse Tendinopathy studies →6 of the 24 studies in Tendinopathy with a site in Turkey are open now. Recruiting first, the newest first:
Acibadem University · Sites in Turkey
Ages 18+
Ankara City Hospital Bilkent · Sites in Turkey
Ages 40–80
Hacettepe University · Sites in Turkey
Ages 18–50
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18–65
Afyonkarahisar Health Sciences University · Sites in Turkey
Ages 18–65
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 46 Tendinopathy studies recruiting now, 17 (37%) set no upper age limit and 22 (48%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is above the median of 48 across 333 interventional studies indexed under Tendinopathy.
Median enrollment 42 across the 19 interventional studies, 100 across the 5 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 24 has an industry lead sponsor. The 10 most frequent:
Fatih Turkmensoy is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Fatih Turkmensoy has 1 study filed under Tendinopathy — fewer than ten, so there is no comparison to draw.
5 of the studies in Tendinopathy with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07722845Acibadem UniversityIllness Perception and Treatment Expectations in Lateral Elbow Pain | 2026-12 |
| NCT06692998Afyonkarahisar Health Sciences UniversityHigh and Low Level Laser Therapy in De Quervain's Tenosynovitis | 2026-12-01 |
| NCT07880522Dr.Rumeysa TürkoğluSubacromial Corticosteroid Injection Combined With Exercise in Supraspinatus Tendinopathy | 2026-12-15 |
| NCT07178418Halic UniversityMuscle Architecture vs Alfredson Protocol in Achilles Tendinopathy | 2026-12-15 |
| NCT07502209Ankara City Hospital BilkentNotch vs Midpoint Suprascapular Nerve PRF for Chronic Shoulder Pain | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 24 studies in Tendinopathy with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study compared three treatments for persistent shoulder pain related to the long head of the biceps tendon. This tendon connects the biceps muscle to the shoulder.
Seventy-five participants were randomly assigned to one of three groups: a steroid injection into the space above the shoulder tendons (the subacromial space), an oral anti-inflammatory medicine (naproxen sodium) taken daily for 28 days, or an ultrasound-guided steroid injection into the sheath around the biceps tendon.
The main outcome was the diameter of the biceps tendon measured by ultrasound four weeks after treatment started. The study also assessed shoulder pain, shoulder function, and difficulty using the arm at four weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-
Exclusion Criteria:Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single subacromial injection of triamcinolone acetonide and bupivacaine using anatomical landmarks.
Drug: Subacromial Triamcinolone Acetonide and Bupivacaine
Participants received oral naproxen sodium once daily for 28 days
Drug: Naproxen Sodium
Participants received a single ultrasound-guided injection of triamcinolone acetonide and bupivacaine into the sheath of the long head of the biceps tendon.
Drug: Ultrasound-Guided Tendon Sheath Triamcinolone Acetonide and Bupivacaine
A single landmark-guided subacromial injection of 1 mL triamcinolone acetonide (40 mg) combined with 9 mL of 0.5% bupivacaine.
Naproxen sodium 750 mg was taken orally once daily for 28 days.
A single ultrasound-guided injection of 1 mL triamcinolone acetonide (40 mg) combined with 9 mL of 0.5% bupivacaine into the sheath of the long head of the biceps tendon.
Long Head of the Biceps Tendon Diameter at Week 4
The diameter of the long head of the biceps tendon was measured by ultrasound at its widest point within the bicipital groove. Two radiologists performed the measurements and determined the final value by consensus.
Time frame: 4 weeks after treatment initiation
QuickDASH Total Score at Week 4
The QuickDASH measures patient-reported upper-extremity disability and symptoms. Scores range from 0 to 100, with higher scores indicating greater disability.
Time frame: 4 weeks after treatment initiation
Constant Score at Week 4
The Constant score measures shoulder function. Scores range from 0 to 100, with higher scores indicating better shoulder function.
Time frame: 4 weeks after treatment initiation
Shoulder Pain Intensity on a Visual Analog Scale at Week 4
Participants rated their shoulder pain on a visual analog scale from 0 to 10, with higher scores indicating greater pain intensity.
Time frame: 4 weeks after treatment initiation
Plan to share: No — There is no plan to share individual participant data with other researchers.
No publications or documents are linked to this record.
Ran from Apr 2021 to primary completion in Sep 2024, 41 months.
Of 174 non-industry interventional studies with no phase under Tendinopathy, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 38. This study's 41 months is above that.
Counting every sponsor, half of 183 studies reached it within 20 months; a quarter within 7 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naproxen
Fatih Turkmensoy